116 related articles for article (PubMed ID: 1467449)
1. Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
De Rosa L; Montuoro A; De Laurenzi A
Biomed Pharmacother; 1992; 46(5-7):211-7. PubMed ID: 1467449
[TBL] [Abstract][Full Text] [Related]
2. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
3. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective observation of curative effects on MDS refractory anemia with combination of all-trans retinoic acid, 1, 25-dihydroxyvitamin D3 and androgen].
Zhou FL; Zhang WG; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Ma XR; Chen G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):861-6. PubMed ID: 16277859
[TBL] [Abstract][Full Text] [Related]
5. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
8. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG).
Hellström E; Robèrt KH; Samuelsson J; Lindemalm C; Grimfors G; Kimby E; Oberg G; Winqvist I; Billström R; Carneskog J
Eur J Haematol; 1990 Nov; 45(5):255-61. PubMed ID: 2261951
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
11. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
Rubio-Felix D; Giraldo P; Franco E; Gimeno J; Giralt M
Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
[TBL] [Abstract][Full Text] [Related]
13. Primary myelodysplastic syndrome: an analysis of 56 patients.
Chen PH; Kuo CY; Huang CH; Shih LY
Changgeng Yi Xue Za Zhi; 1992 Sep; 15(3):121-7. PubMed ID: 1468034
[TBL] [Abstract][Full Text] [Related]
14. [Effect of treatment with 13-cis-retinoic acid and ara-C on the hematopoietic stem cells of patients with myelodysplastic syndromes].
García Marco J; Miguel Sosa A; García Conde J; Miguel García A; Arbona C; Escrig V; Benet I; Navarro I; Ruiz A; Carbonell F
Sangre (Barc); 1994 Aug; 39(4):241-4. PubMed ID: 7985051
[TBL] [Abstract][Full Text] [Related]
15. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
[TBL] [Abstract][Full Text] [Related]
16. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
17. [Low dose all-trans retinoic acid and androgen therapy for patients with myelodysplastic syndrome].
Guan M; Chen SC; Li RS; Ge CW; Zhu HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):774-8. PubMed ID: 15631659
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplastic syndromes--a population-based study on transformation and survival.
Hörnsten P; Wahlin A; Rudolphi O; Nordenson I
Acta Oncol; 1995; 34(4):473-8. PubMed ID: 7605654
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
20. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
